Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Multiple Myeloma 3Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Cyclophosphamide 13Bevacizumab 9Interleukin-2 8aldesleukin 7Paclitaxel 7fludarabine phosphate 6fludarabine 6Radiotherapy 6Bortezomib 6Thalidomide 5Gemcitabine 5Filgrastim 5veliparib 4sargramostim 4Vincristine 4Trastuzumab 4Prednisone 4Leucovorin 4Doxorubicin 4Biopsy 4vandetanib 3tariquidar 3romidepsin 3pazopanib 3montanide ISA 51 3Topotecan 3Specimen Handling 3Sorafenib 3Sirolimus 3Oxaliplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neoplasms × Receptors, Chimeric Antigen × Clear all
NCT00924287 2015-10-28

Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
1 enrolled 8 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡